JP2007513608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513608A5 JP2007513608A5 JP2006538786A JP2006538786A JP2007513608A5 JP 2007513608 A5 JP2007513608 A5 JP 2007513608A5 JP 2006538786 A JP2006538786 A JP 2006538786A JP 2006538786 A JP2006538786 A JP 2006538786A JP 2007513608 A5 JP2007513608 A5 JP 2007513608A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- ghrelin
- biologically active
- acid according
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 102000012004 Ghrelin Human genes 0.000 claims 15
- 101800001586 Ghrelin Proteins 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000000975 bioactive effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 150000003838 adenosines Chemical class 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- -1 n-octanoyl ghrelin Chemical compound 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000027796 Blood pressure disease Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 108091027076 Spiegelmer Proteins 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000006583 body weight regulation Effects 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03025743.0 | 2003-11-10 | ||
| EP03025743 | 2003-11-10 | ||
| PCT/EP2004/012739 WO2005049828A1 (en) | 2003-11-10 | 2004-11-10 | Nucleic acids specifically binding bioactive ghrelin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513608A JP2007513608A (ja) | 2007-05-31 |
| JP2007513608A5 true JP2007513608A5 (enExample) | 2007-12-27 |
| JP4823067B2 JP4823067B2 (ja) | 2011-11-24 |
Family
ID=34610046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538786A Expired - Fee Related JP4823067B2 (ja) | 2003-11-10 | 2004-11-10 | 生物活性グレリンに特異的に結合する核酸 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20070031840A1 (enExample) |
| EP (1) | EP1682662A1 (enExample) |
| JP (1) | JP4823067B2 (enExample) |
| KR (1) | KR20060125743A (enExample) |
| CN (1) | CN1894407A (enExample) |
| AP (1) | AP2006003618A0 (enExample) |
| AU (1) | AU2004291656A1 (enExample) |
| BR (1) | BRPI0415872A (enExample) |
| CA (1) | CA2544805A1 (enExample) |
| CR (1) | CR8388A (enExample) |
| EA (1) | EA009376B1 (enExample) |
| EC (1) | ECSP066559A (enExample) |
| IL (1) | IL175443A0 (enExample) |
| MA (1) | MA28153A1 (enExample) |
| NO (1) | NO20062663L (enExample) |
| OA (1) | OA13282A (enExample) |
| TN (1) | TNSN06132A1 (enExample) |
| WO (1) | WO2005049828A1 (enExample) |
| ZA (1) | ZA200603435B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4644599B2 (ja) * | 2002-08-01 | 2011-03-02 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | グレリン結合核酸 |
| EP2290070B1 (en) * | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| ES2534302T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| AR052741A1 (es) | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| EP2115138A2 (en) * | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| AU2007333109A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
| AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008154333A2 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
| WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| US20090192114A1 (en) * | 2007-12-21 | 2009-07-30 | Dmitriy Ovcharenko | miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
| EP2260110B1 (en) * | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| WO2009111643A2 (en) * | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
| US20090253780A1 (en) * | 2008-03-26 | 2009-10-08 | Fumitaka Takeshita | COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| US20110105389A1 (en) | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
| AU2012206750A1 (en) * | 2011-01-10 | 2013-07-18 | Noxxon Pharma Ag | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614395A (en) * | 1988-03-08 | 1997-03-25 | Ciba-Geigy Corporation | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof |
| DE69128350T2 (de) * | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| EP0825997A1 (en) * | 1995-05-03 | 1998-03-04 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
| US5780221A (en) * | 1995-05-03 | 1998-07-14 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
| US20030211967A1 (en) * | 2001-05-07 | 2003-11-13 | Bryant Henry Uhlman | Method for selectively inhibiting ghrelin action |
| EP1286697A2 (en) * | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| US6967237B2 (en) * | 2000-05-30 | 2005-11-22 | Merck & Co., Inc. | Ghrelin analogs |
| JP4644599B2 (ja) * | 2002-08-01 | 2011-03-02 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | グレリン結合核酸 |
| AR052741A1 (es) * | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
-
2004
- 2004-11-10 CA CA002544805A patent/CA2544805A1/en not_active Abandoned
- 2004-11-10 BR BRPI0415872-5A patent/BRPI0415872A/pt not_active IP Right Cessation
- 2004-11-10 CN CNA2004800377977A patent/CN1894407A/zh active Pending
- 2004-11-10 AP AP2006003618A patent/AP2006003618A0/xx unknown
- 2004-11-10 US US10/578,938 patent/US20070031840A1/en not_active Abandoned
- 2004-11-10 EA EA200600735A patent/EA009376B1/ru not_active IP Right Cessation
- 2004-11-10 JP JP2006538786A patent/JP4823067B2/ja not_active Expired - Fee Related
- 2004-11-10 OA OA1200600147A patent/OA13282A/en unknown
- 2004-11-10 AU AU2004291656A patent/AU2004291656A1/en not_active Abandoned
- 2004-11-10 EP EP04797787A patent/EP1682662A1/en not_active Ceased
- 2004-11-10 KR KR1020067009024A patent/KR20060125743A/ko not_active Withdrawn
- 2004-11-10 WO PCT/EP2004/012739 patent/WO2005049828A1/en not_active Ceased
-
2006
- 2006-05-02 ZA ZA200603435A patent/ZA200603435B/en unknown
- 2006-05-04 IL IL175443A patent/IL175443A0/en unknown
- 2006-05-09 TN TNP2006000132A patent/TNSN06132A1/fr unknown
- 2006-05-10 EC EC2006006559A patent/ECSP066559A/es unknown
- 2006-05-10 MA MA29015A patent/MA28153A1/fr unknown
- 2006-05-10 CR CR8388A patent/CR8388A/es not_active Application Discontinuation
- 2006-06-09 NO NO20062663A patent/NO20062663L/no not_active Application Discontinuation
-
2010
- 2010-02-24 US US12/711,415 patent/US20100261291A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513608A5 (enExample) | ||
| Jain et al. | Potential biomarkers and their applications for rapid and reliable detection of malaria | |
| Yao et al. | Hybridization assay of hepatitis B virus by QCM peptide nucleic acid biosensor | |
| JP4441618B2 (ja) | インフルエンザウイルスの検出方法 | |
| EP3085786B1 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
| TW200844238A (en) | HLA alleles associated with adverse drug reactions and methods for detecting such | |
| CA2455731A1 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
| JP2008509672A5 (enExample) | ||
| JP6997709B2 (ja) | 全身性炎症反応症候群（ｓｉｒｓ）患者における合併症リスクを評価する方法 | |
| CN110004149A (zh) | 一种程序性死亡受体-配体1的核酸适体及其应用 | |
| JP2017532961A (ja) | Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物 | |
| Wolf et al. | Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment | |
| US11634717B2 (en) | DNA aptamer specifically binding to TB7.7, and use thereof | |
| US11619633B2 (en) | DNA aptamer specifically binding to ESAT6, and use thereof | |
| JP2004113094A (ja) | 高血圧のリスク診断方法 | |
| WO2017148432A1 (zh) | 用于预测慢性乙肝患者对IFNα治疗的应答的方法和试剂盒 | |
| KR20140054905A (ko) | 당화혈색소에 특이적 앱타머 및 이를 포함하는 당화혈색소 검출용 조성물 | |
| KR20120092938A (ko) | 알파태아단백질에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| JP2009511026A5 (enExample) | ||
| WO2006080262A1 (ja) | Ａｇｅ－２アプタマー | |
| AU2005282636B2 (en) | Methods for assessing atherosclerosis | |
| JP2006101790A (ja) | 高血圧症のリスクの評価方法 | |
| WO2018128286A1 (ko) | 핵산의 신속 검출법 및 이를 이용한 질병의 신속 진단 방법 | |
| Datta et al. | Electrochemical detection of cancer fingerprint: a systematic review on recent progress in extracellular vesicle research from lab to market | |
| US20200325475A1 (en) | Dna aptamer specifically binding to cfp10, and use thereof |